Advances and Novel Perspectives in Mineralocorticoid Receptor Antagonism-Advances and Novel Perspectives in Mineralocorticoid Receptor Antagonism

Video Transcription

Video Summary

Summary:<br /><br />The video summaries describe a symposium on mineralocorticoid receptor antagonism and its potential benefits in various health conditions. The first speaker discusses the development of non-steroidal mineralocorticoid receptor antagonists, which show promise in reducing side effects and improving clinical outcomes. One drug, finerenone, shows significant reduction in cardiovascular and renal outcomes in patients with chronic kidney disease and type 2 diabetes. Other potential applications of these antagonists are mentioned, including obesity, skin diseases, eye diseases, inflammation, and cardio-renal injury.<br /><br />In another presentation, the impact of aldosterone levels on women and the role of endothelial cells in vascular homeostasis are discussed. Research conducted by Dr. Buer shows that the expression of mineralocorticoid receptors in endothelial cells is higher in obese females. MR inhibition in obese females improves vasodilation by increasing the expression of ER-alpha. Further studies demonstrate that MR and ER-alpha compete for binding to a protein called striatin, which regulates endothelial function. These findings suggest that MR antagonists can be beneficial for improving endothelial function in obese females.<br /><br />(No credits were mentioned in the provided summary.)

Keywords

symposium

mineralocorticoid receptor antagonism

health conditions

non-steroidal mineralocorticoid receptor antagonists

finerenone

cardiovascular outcomes

renal outcomes

chronic kidney disease

type 2 diabetes

obesity

endothelial cells

vascular homeostasis


EndoCareers \| Contact Us \| Privacy Policy \| Terms of Use	CONNECT WITH US
© 2021 Copyright Endocrine Society. All rights reserved.	2055 L Street NW, Suite 600 \| Washington, DC 20036 202.971.3636 \| 888.363.6274